• Technology
  • Applications
    • AML MRD
    • Mutagenesis
    • Cellular Immunotherapy
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
    • Investors
  • Contact
TwinStrand Biosciences
  • Technology
  • Applications
    • AML MRD
    • Mutagenesis
    • Cellular Immunotherapy
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
    • Investors
  • Contact

 

Duplex Sequencing solves genetic
needle-in-a-haystack challenges

 

(click to expand)

 

Duplex Sequencing is a fundamentally enabling platform technology for rare variant detection with many diverse applications. TwinStrand has purpose-built solutions for mutagenesis and AML MRD available now with more applications currently in development.

Explore Applications and Publications

 

    AML MRD    

    Mutagenesis    

Cellular Immunotherapy

Collaboration

Publications

 

TwinStrand Biosciences, Inc.
3131 Elliott Ave, Suite 750 • Seattle, WA 98121 • USA
+1 (877) 202-TWIN

 

For Research Use Only. Not for use in diagnostic procedures.

©2022 TwinStrand Biosciences, Inc. All rights reserved. All trademarks are the property of TwinStrand Biosciences, Inc. or their respective owners.  Legal Notices

  

American Society of Hematology (ASH)

December 5-8, 2020 – Virtual

 

Poster Presentation

 

“Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia”

 

Presented by Jake Higgins, Senior Scientist – December 6, 2020 7:00 a.m.-3:30 p.m. PST

 

Conference Website

 

Society of Toxicology (SOT)

March 10-14, 2019 – Baltimore, MD

 

Poster Presentations

 

 

View Poster

 

 

Conference Website

 

AACR Annual Meeting – San Diego, CA

March 29-April 3, 2019

 

Poster Presentations

 

 

View Poster

 

 

View Poster

Presentations by CEO Jesse Salk, MD, PhD – AGBT 2020

Ultra-Sensitive Residual Leukemia Detection with Patient-Specific Dupex Sequencing